Health
Testosterone Therapy
FDA Signals End to Restrictions on Testosterone Therapy for Age-Related Low T After Removing Black Box Warning
3 sources · 11d ago
Factlen Explainer
Landmark Approval: First Drug Proven to Cut Acute Pancreatitis Risk in Severe Hypertriglyceridemia
4 sources · 11d ago
Factlen Explainer
Landmark Approval: First Drug Proven to Cut Acute Pancreatitis Risk in Severe Hypertriglyceridemia
4 sources · 11d ago
More in Health
Antibiotic ResistanceExplainer
FDA Approves Utebzi as First Oral Carbapenem Antibiotic for Complicated UTIs
Infectious Disease Specialists 35%Patients and Caregivers 35%Healthcare Economists 30%
6 sources · 11d ago
Menopause CareExplainer
Landmark 20-Year WHI Follow-up Reverses Hormone Therapy Fears for Younger Menopausal Women
Medical Consensus 50%Patient Advocates 30%Cautious Oncologists 20%
4 sources · 11d ago
Menopause CareExplainer
Landmark 20-Year WHI Follow-up Reverses Hormone Therapy Fears for Younger Menopausal Women
Medical Consensus 50%Patient Advocates 30%Cautious Oncologists 20%
4 sources · 11d ago
Factlen ExplainerProstate Cancer
Landmark Trial: Perioperative Apalutamide Improves Metastasis-Free Survival in Localized High-Risk Prostate Cancer
Clinical Investigators 45%Surgical Urologists 35%Pharmaceutical Developers 20%
5 sources · 11d ago
Factlen ExplainerProstate Cancer
Landmark Trial: Perioperative Apalutamide Improves Metastasis-Free Survival in Localized High-Risk Prostate Cancer
Clinical Investigators 45%Surgical Urologists 35%Pharmaceutical Developers 20%
5 sources · 11d ago
Factlen ResearchPsychedelic Medicine
Psilocybin Completes Second Pivotal Phase 3 Trial, Paving Way for FDA Review in Depression
Clinical Researchers 41%Regulatory Pragmatists 35%Healthcare Economists 24%
5 sources · 11d ago
Factlen ResearchPsychedelic Medicine
Psilocybin Completes Second Pivotal Phase 3 Trial, Paving Way for FDA Review in Depression
Clinical Researchers 41%Regulatory Pragmatists 35%Healthcare Economists 24%
5 sources · 11d ago
CRISPR MilestoneExplainer
Single-Dose In-Vivo CRISPR Therapy Achieves World's First Phase 3 Win, Validating Gene Editing Platform
Gene Editing Researchers 38%HAE Patient Advocates 38%Biotech Analysts 25%
3 sources · 11d ago
CRISPR MilestoneExplainer
Single-Dose In-Vivo CRISPR Therapy Achieves World's First Phase 3 Win, Validating Gene Editing Platform
Gene Editing Researchers 38%HAE Patient Advocates 38%Biotech Analysts 25%
3 sources · 11d ago
Type 1 DiabetesMedical Breakthrough
FDA Approves First Drug to Delay Type 1 Diabetes Progression, Shifting Focus to Immune Intervention
Endocrinologists & Researchers 40%Patients & Families 35%Regulatory & Safety Watchdogs 25%
4 sources · 11d ago
Regenerative MedicineClinical Milestone
First-in-Human Trial Shows Stem Cell Transplant for Parkinson's Disease is Feasible and Safe
Regenerative Medicine Researchers 45%Biotech and Industry Developers 30%Patient Advocacy Organizations 25%
3 sources · 11d ago
Regenerative MedicineClinical Milestone
First-in-Human Trial Shows Stem Cell Transplant for Parkinson's Disease is Feasible and Safe
Regenerative Medicine Researchers 45%Biotech and Industry Developers 30%Patient Advocacy Organizations 25%
3 sources · 11d ago
Factlen ExplainerPsychiatric Medicine
First New Class of Schizophrenia Drug in Decades Targets Muscarinic Receptors, Halving Symptoms
Clinical Psychiatrists 40%Patient Advocates 35%Neuropharmacologists 25%
4 sources · 11d ago
Factlen ExplainerPsychiatric Medicine
First New Class of Schizophrenia Drug in Decades Targets Muscarinic Receptors, Halving Symptoms
Clinical Psychiatrists 40%Patient Advocates 35%Neuropharmacologists 25%
4 sources · 11d ago
Dental ImagingTech Breakthrough
FDA Clears First-Ever Dental-Dedicated MRI for Non-Ionizing Soft-Tissue Diagnostics
Diagnostic Innovators 45%Clinical Specialists 40%Healthcare Economists 15%
4 sources · 12d ago
Factlen ExplainerJoint Health
Landmark Research: Single Injection Reverses Cartilage Loss in Joints, Offering Potential Alternative to Knee Replacement
Regenerative Medicine Researchers 45%Clinical Evaluators 30%Healthcare Economists & Analysts 25%
3 sources · 12d ago
Precision OncologyExplainer
Landmark Trial: Combination of Talazoparib and Enzalutamide Halves Progression Risk in Metastatic Prostate Cancer
Clinical Oncologists 40%Precision Medicine Advocates 30%Patient Quality-of-Life Researchers 30%
4 sources · 12d ago
Factlen ExplainerOncology Breakthrough
Landmark Trial Cracks 'Undruggable' KRAS Target, Delivering Unprecedented Survival Advantage in Pancreatic Cancer
Targeted Therapy Advocates 45%Structural Biologists 30%Access & Policy Watchdogs 25%
7 sources · 12d ago
Peptide RegulationExplainer
The Evidence Pack: How an Imminent FDA Hearing Will Decide the Fate of BPC-157 and TB-500
Biohackers & Longevity Advocates 40%Regulatory & Safety Officials 35%Compounding Pharmacists 25%
2 sources · 12d ago
Epigenetic ReprogrammingClinical Trial
First Human Trial of Cellular Reprogramming Drug Begins, Targeting Age Reversal in the Optic Nerve
Longevity Biotech Advocates 45%Clinical Ophthalmologists 35%Safety & Regulatory Monitors 20%
3 sources · 12d ago
Epigenetic ReprogrammingClinical Trial
First Human Trial of Cellular Reprogramming Drug Begins, Targeting Age Reversal in the Optic Nerve
Longevity Biotech Advocates 45%Clinical Ophthalmologists 35%Safety & Regulatory Monitors 20%
3 sources · 12d ago
Factlen ResearchLongevity Medicine
Landmark $38M Trial Tests Rapamycin, GLP-1, and SGLT2 Inhibitors as First Longevity Drugs in Healthy Adults
Geroscience Innovators 45%Clinical Evidence Pragmatists 35%Regulatory & Safety Watchdogs 20%
4 sources · 12d ago
Factlen ResearchLongevity Medicine
Landmark $38M Trial Tests Rapamycin, GLP-1, and SGLT2 Inhibitors as First Longevity Drugs in Healthy Adults
Geroscience Innovators 45%Clinical Evidence Pragmatists 35%Regulatory & Safety Watchdogs 20%
4 sources · 12d ago